Update on the use of memantine in Alzheimer’s disease
Robert J van MarumGeriatric Department, University Medical Center Utrecht, Utrecht, The NetherlandsAbstract: Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) antagonist. The effects of memantine in Alzheimer’s disease (AD) have been studied in 7 randomized...
Guardado en:
Autor principal: | Robert J van Marum |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/218ef8e1e7274df2acf44374ca1371af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Umamon Puangthong, et al.
Publicado: (2009) -
An update on the toxicity of Aβ in Alzheimer’s disease
por: Jürgen Götz, et al.
Publicado: (2008) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013) -
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
por: Hoogveldt B, et al.
Publicado: (2011) -
Update on ropinirole in the treatment of Parkinson’s disease
por: Holly A Shill, et al.
Publicado: (2008)